Which has preferable valuation and earnings, RNAC or RADX?

Radiopharm Theranostics has lower revenue, but higher earnings than Cartesian Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cartesian Therapeutics $2.80M 72.61 -$130.30M -$5.90 N/A Radiopharm Theranostics $2.35M 23.52 -$24.83M N/A N/A

Is RNAC or RADX more profitable?

Radiopharm Theranostics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics -8,550.65% N/A -28.25% Radiopharm Theranostics N/A N/A N/A

Which has preferable earnings and valuation, RADX or IMUX?

Radiopharm Theranostics has higher revenue and earnings than Immunic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 23.52 -$24.83M N/A N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is RADX or IMUX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Immunic N/A -220.75% -132.04%

Which has stronger earnings and valuation, ELTX or RADX?

Radiopharm Theranostics has higher revenue and earnings than Elicio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A Radiopharm Theranostics $2.35M 23.52 -$24.83M N/A N/A

Is ELTX or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Radiopharm Theranostics N/A N/A N/A

Which has stronger valuation & earnings, ANIK or RADX?

Anika Therapeutics has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anika Therapeutics $112.82M 1.73 -$10.88M -$0.79 N/A Radiopharm Theranostics $2.35M 23.52 -$24.83M N/A N/A

Which has better valuation & earnings, ARTV or RADX?

Radiopharm Theranostics has higher revenue and earnings than Artiva Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics $250K 737.64 -$83.86M -$3.54 N/A Radiopharm Theranostics $2.35M 23.52 -$24.83M N/A N/A

Is ARTV or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Radiopharm Theranostics N/A N/A N/A

Radiopharm Theranostics (RADX) Competitors

$4.68 +0.10 (+2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$4.61 -0.07 (-1.50%)

As of 07:37 PM Eastern

Compare

RADX vs. RNAC, IMUX, ELTX, ANIK, and ARTV

Should you buy Radiopharm Theranostics stock or one of its competitors? MarketBeat compares Radiopharm Theranostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Radiopharm Theranostics include Cartesian Therapeutics (RNAC), Immunic (IMUX), Elicio Therapeutics (ELTX), Anika Therapeutics (ANIK), and Artiva Biotherapeutics (ARTV). These companies are all part of the "med - biomed/gene" industry.

How does Radiopharm Theranostics compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Cartesian Therapeutics had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 5 mentions for Cartesian Therapeutics and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.89 beat Cartesian Therapeutics' score of 0.17 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cartesian Therapeutics	Neutral
Radiopharm Theranostics	Very Positive

Cartesian Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

Radiopharm Theranostics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Radiopharm Theranostics	N/A	N/A	N/A

Cartesian Therapeutics currently has a consensus price target of $32.60, indicating a potential upside of 371.10%. Radiopharm Theranostics has a consensus price target of $16.00, indicating a potential upside of 241.88%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Radiopharm Theranostics has lower revenue, but higher earnings than Cartesian Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	72.61	-$130.30M	-$5.90	N/A
Radiopharm Theranostics	$2.35M	23.52	-$24.83M	N/A	N/A

Summary

Cartesian Therapeutics beats Radiopharm Theranostics on 8 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Immunic?

Radiopharm Theranostics (NASDAQ:RADX) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Radiopharm Theranostics currently has a consensus price target of $16.00, suggesting a potential upside of 241.88%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 214.42%. Given Radiopharm Theranostics' higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Radiopharm Theranostics has higher revenue and earnings than Immunic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	23.52	-$24.83M	N/A	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Radiopharm Theranostics' return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Immunic	N/A	-220.75%	-132.04%

51.8% of Immunic shares are owned by institutional investors. 14.0% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Immunic had 5 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 6 mentions for Immunic and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.89 beat Immunic's score of 0.73 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Overall Sentiment
Radiopharm Theranostics	Very Positive
Immunic	Positive

Radiopharm Theranostics has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Summary

Immunic beats Radiopharm Theranostics on 7 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Elicio Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

35.0% of Elicio Therapeutics shares are owned by institutional investors. 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Elicio Therapeutics presently has a consensus price target of $18.00, indicating a potential upside of 48.51%. Radiopharm Theranostics has a consensus price target of $16.00, indicating a potential upside of 241.88%. Given Radiopharm Theranostics' higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Radiopharm Theranostics' return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Radiopharm Theranostics	N/A	N/A	N/A

Radiopharm Theranostics has higher revenue and earnings than Elicio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Radiopharm Theranostics	$2.35M	23.52	-$24.83M	N/A	N/A

In the previous week, Elicio Therapeutics had 7 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 8 mentions for Elicio Therapeutics and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.89 beat Elicio Therapeutics' score of -0.26 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Elicio Therapeutics	Neutral
Radiopharm Theranostics	Very Positive

Summary

Radiopharm Theranostics beats Elicio Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Anika Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Anika Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 16.20%. Radiopharm Theranostics has a consensus target price of $16.00, suggesting a potential upside of 241.88%. Given Radiopharm Theranostics' higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Radiopharm Theranostics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -9.52%. Radiopharm Theranostics' return on equity of 0.00% beat Anika Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
Radiopharm Theranostics	N/A	N/A	N/A

91.5% of Anika Therapeutics shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Anika Therapeutics has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.73	-$10.88M	-$0.79	N/A
Radiopharm Theranostics	$2.35M	23.52	-$24.83M	N/A	N/A

In the previous week, Anika Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.89 beat Anika Therapeutics' score of 0.94 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anika Therapeutics	Positive
Radiopharm Theranostics	Very Positive

Summary

Radiopharm Theranostics beats Anika Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Artiva Biotherapeutics had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 5 mentions for Artiva Biotherapeutics and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.89 beat Artiva Biotherapeutics' score of 0.97 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Artiva Biotherapeutics	Positive
Radiopharm Theranostics	Very Positive

Artiva Biotherapeutics presently has a consensus target price of $39.00, indicating a potential upside of 422.79%. Radiopharm Theranostics has a consensus target price of $16.00, indicating a potential upside of 241.88%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Artiva Biotherapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Radiopharm Theranostics has higher revenue and earnings than Artiva Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	737.64	-$83.86M	-$3.54	N/A
Radiopharm Theranostics	$2.35M	23.52	-$24.83M	N/A	N/A

Radiopharm Theranostics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Artiva Biotherapeutics beats Radiopharm Theranostics on 7 of the 12 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.11M	$3.40B	$6.43B	$12.56B
Dividend Yield	N/A	2.29%	2.69%	5.30%
P/E Ratio	N/A	17.92	21.32	26.62
Price / Sales	23.52	334.54	551.43	114.14
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	1.33	6.84	9.95	6.88
Net Income	-$24.83M	$24.15M	$3.56B	$336.73M
7 Day Performance	1.08%	1.93%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	-2.30%	62.98%	36.32%	40.26%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	2.8234 of 5 stars	$4.68 +2.2%	$16.00 +241.9%	-4.4%	$54.11M	$2.35M	N/A	N/A	Positive News
RNAC Cartesian Therapeutics	2.8601 of 5 stars	$7.54 +4.6%	$32.60 +332.4%	-21.1%	$211.84M	$2.80M	N/A	64
IMUX Immunic	3.1414 of 5 stars	$14.96 -0.1%	$47.57 +218.0%	+127.0%	$203.91M	N/A	N/A	70	Analyst Forecast
ELTX Elicio Therapeutics	1.8847 of 5 stars	$11.44 +7.8%	$18.00 +57.3%	+58.2%	$202.50M	N/A	N/A	N/A	News Coverage Analyst Revision
ANIK Anika Therapeutics	2.3898 of 5 stars	$14.53 -2.5%	$17.00 +17.0%	+29.7%	$198.25M	$112.82M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. RNAC, IMUX, ELTX, ANIK, and ARTV

How does Radiopharm Theranostics compare to Cartesian Therapeutics?

Summary

How does Radiopharm Theranostics compare to Immunic?

Summary

How does Radiopharm Theranostics compare to Elicio Therapeutics?

Summary

How does Radiopharm Theranostics compare to Anika Therapeutics?

Summary

How does Radiopharm Theranostics compare to Artiva Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. RNAC, IMUX, ELTX, ANIK, and ARTV

How does Radiopharm Theranostics compare to Cartesian Therapeutics?

Does the media favor RNAC or RADX?

Which has more risk and volatility, RNAC or RADX?

Is RNAC or RADX more profitable?

Do analysts rate RNAC or RADX?

Do insiders and institutionals have more ownership in RNAC or RADX?

Which has preferable valuation and earnings, RNAC or RADX?

Summary

How does Radiopharm Theranostics compare to Immunic?

Do analysts recommend RADX or IMUX?

Which has preferable earnings and valuation, RADX or IMUX?

Is RADX or IMUX more profitable?

Do insiders & institutionals hold more shares of RADX or IMUX?

Does the media prefer RADX or IMUX?

Which has more risk & volatility, RADX or IMUX?

Summary

How does Radiopharm Theranostics compare to Elicio Therapeutics?

Which has more volatility and risk, ELTX or RADX?

Do insiders and institutionals have more ownership in ELTX or RADX?

Do analysts rate ELTX or RADX?

Is ELTX or RADX more profitable?

Which has stronger earnings and valuation, ELTX or RADX?

Does the media refer more to ELTX or RADX?

Summary

How does Radiopharm Theranostics compare to Anika Therapeutics?

Which has more volatility & risk, ANIK or RADX?

Do analysts rate ANIK or RADX?

Is ANIK or RADX more profitable?

Do insiders & institutionals hold more shares of ANIK or RADX?

Which has stronger valuation & earnings, ANIK or RADX?

Does the media prefer ANIK or RADX?

Summary

How does Radiopharm Theranostics compare to Artiva Biotherapeutics?

Does the media prefer ARTV or RADX?

Do analysts rate ARTV or RADX?

Which has more volatility & risk, ARTV or RADX?

Which has better valuation & earnings, ARTV or RADX?

Is ARTV or RADX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools